ALS Research Funding Cuts Threaten Hope for Genetic Carriers

For almost a decade, I’ve fought for a cure for a disease I don’t even have yet. The prospect of finding effective treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) feels increasingly distant with the shift in political priorities under the second Trump administration. It’s a chilling reality for those of us carrying the genetic mutation that predisposes us to these devastating conditions.

In 2018, I learned I carried the C9orf72 mutation, the most common genetic cause of both ALS and FTD. This meant I faced a significant risk of developing either disease, a shadow hanging over my life as I navigated my husband’s cancer treatment and the needs of our young children. I channeled my anxiety into action, participating in over a dozen research studies, clinging to the hope that scientific progress would outpace my genetic destiny. I believed, as many did, that breakthroughs were within reach.

A Brief Respite, Then a Setback

The passage of ACT for ALS in 2021, allocating substantial funding to ALS research, felt like a turning point. The FDA approval of Qalsody (tofersen) in 2023, a treatment for ALS patients with a SOD1 mutation, further fueled optimism. The hope was that success with genetic forms of ALS would pave the way for treatments targeting other mutations, including C9orf72. A friend carrying the C9 mutation even enrolled in a clinical trial at Massachusetts General Hospital, testing the repurposed drug baricitinib as a preventative measure. He became a symbol of hope for our community.

Although, that hope has been significantly dimmed. With the return of Donald Trump to office, funding for medical research at institutions like Harvard and Mass General has been slashed. The ALLFTD study, a crucial longitudinal research project for FTD, was forced to pause due to defunding. This isn’t merely an abstract budgetary issue; it has direct, devastating consequences for those of us living with the threat of these diseases.

The Personal Toll of Defunding

Just two months ago, my friend participating in the baricitinib trial received a diagnosis of ALS. His ability to access ongoing research and potential treatments is now uncertain. I fear he, and countless others like him, will be denied the chance to benefit from scientific advancements that were within reach just a short time ago. The cuts aren’t just impacting research; they’re eroding the particularly foundation of hope for those of us carrying these genetic burdens.

The systematic dismantling of research initiatives feels particularly cruel to those of us who have invested so much – time, money, and emotional energy – in the pursuit of a cure. It’s a betrayal of the trust we placed in the scientific community and the promise of progress. The current administration’s actions are not simply delaying research; they are actively denying patients access to potentially life-saving advancements.

Beyond Funding: Broader Concerns for Public Health

My concerns extend beyond research funding. The policies of the current health secretary, Robert F. Kennedy Jr., and the resulting rise in preventable diseases like measles, threaten to overwhelm the healthcare system. This could further delay ALS diagnoses and limit access to specialized care. The already lengthy process of drug development and approval – often taking a decade or more – is likely to be exacerbated by these broader systemic challenges.

Understanding the C9orf72 Mutation

The C9orf72 mutation involves an expansion of a DNA sequence within the C9orf72 gene. Healthy individuals typically have fewer than 30 repeats of this sequence, while those affected by ALS or FTD can have hundreds or even thousands. This expansion leads to several pathological mechanisms, including a loss of normal protein function, the formation of RNA clumps, and the production of toxic proteins. Researchers are still working to fully understand how these mechanisms contribute to disease development.

What Does This Mean for the Future?

The recent setbacks are not merely a temporary pause in progress; they represent a fundamental shift in priorities. The erosion of support for medical research has far-reaching consequences, not only for those affected by ALS and FTD but for the entire scientific community. It sends a message that scientific inquiry is not valued, and that the pursuit of knowledge is secondary to political agendas.

I, along with countless others in the ALS community, refuse to be silenced. We will continue to advocate for increased research funding, access to clinical trials, and policies that prioritize the health and well-being of all citizens. My children deserve a future free from the fear of inheriting this devastating disease, and I will fight tirelessly to ensure that future becomes a reality. The stakes are too high to remain silent.

Mindy Uhrlaub is the author of “Last Nerve: A Memoir of Illness and the Endurance of Family.”